---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-036032"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2021-07-08T23:59:59+00:00"
generated_at: "2026-06-30T06:37:04.566713+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aeglea Biotherapeutics appoints Jonathan Alspaugh as CFO effective July 6, 2021

## Summary
- Jonathan Alspaugh (38) named CFO; was Managing Director at Evercore's Corporate Advisory business from April 2013 to June 2021.
- Annual base salary of $400,008; eligible for cash bonus up to 40% of base salary based on performance criteria.
- Granted option to purchase 160,000 shares of common stock at closing price on July 6, 2021.
- Option vests 1/4th after one year and 1/48th monthly thereafter, subject to continued service.
- Company entered standard indemnification agreement with Alspaugh.

## SEC filing metadata
- accession: 0001564590-21-036032
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2021-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000156459021036032/0001564590-21-036032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000156459021036032/agle-8k_20210708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-036032
- JSON: https://secwatch.observer/filing/0001564590-21-036032.json
- Plain text: https://secwatch.observer/filing/0001564590-21-036032.txt

## Key facts
- Executive change
  Jonathan Alspaugh was appointed as Chief Financial Officer at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 23, 2021, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jonathan Alspaugh, age 38, as Chief Financial Officer, effective July 6, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000156459021036032/0001564590-21-036032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.